| <SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: " New?? Courier> 加拿大卫生部与罗氏公司</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-ascii-font-family: " Roman?? New Times>（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; mso-font-kerning: 0pt">Hoffmann-La Roche</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-ascii-font-family: " Roman?? New Times>）于</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: " New?? Courier>2009年4月1日发布</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: " New?? Courier>特罗凯</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%">(</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; mso-bidi-font-weight: bold; mso-font-kerning: 0pt">TARCEVA/erlotinib)</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-weight: bold; mso-font-kerning: 0pt; mso-bidi-font-family: 宋体">的安全性信息。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; mso-bidi-font-weight: bold; mso-font-kerning: 0pt">Tarceva</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-weight: bold; mso-font-kerning: 0pt">为</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体">表皮生长因子受体酪氨酸激酶抑制剂</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: " New?? Courier>，</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体">适用于治疗恶性肿瘤，尤其适用晚期非小细胞肺癌。</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: " New?? Courier>上市后监测显示接受</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; mso-bidi-font-weight: bold; mso-font-kerning: 0pt">Tarceva</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: " New?? Courier>治疗的患者中出现数例</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: Arial">胃肠道穿孔、</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%">Stevens-Johnson</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: Arial">综合症、</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-family: " New?? Courier>角膜穿孔的不良反应报告。</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-font-kerning: 0pt; mso-bidi-font-family: " New?? Courier>罗氏公司提醒处方者一旦患者出现上述不良反应，应立即停用</SPAN><SPAN lang=EN-US style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-weight: bold; mso-font-kerning: 0pt">Tarceva</SPAN><SPAN style="FONT-SIZE: 12pt; COLOR: black; LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; mso-bidi-font-weight: bold; mso-font-kerning: 0pt">。</SPAN> |
